Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)

- The report reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Post-Traumatic Stress Disorder (PTSD) therapeutics and enlists all their major and minor projects

- The report assesses Post-Traumatic Stress Disorder (PTSD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Actinogen Medical Ltd

Addex Therapeutics Ltd

Amorsa Therapeutics Inc

Anagin Inc

Aptinyx Inc

Armgo Pharma Inc

Artelo Biosciences Inc

Azevan Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc ...

Actinogen Medical Ltd

Addex Therapeutics Ltd

Amorsa Therapeutics Inc

Anagin Inc

Aptinyx Inc

Armgo Pharma Inc

Artelo Biosciences Inc

Azevan Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Eli Lilly and Co

Embera NeuroTherapeutics Inc

Immodulon Therapeutics Ltd

Johnson & Johnson

Lixte Biotechnology Holdings Inc

NeuroNascent Inc

Omeros Corp

Otsuka Holdings Co Ltd

Sanofi

SpringWorks Therapeutics LLC

Tonix Pharmaceuticals Holding Corp

Table of Contents

Table of Contents

Table of Contents

Introduction

Post-Traumatic Stress Disorder (PTSD) - Overview

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment

Post-Traumatic ...

Table of Contents

Table of Contents

Introduction

Post-Traumatic Stress Disorder (PTSD) - Overview

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment

Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development

Post-Traumatic Stress Disorder (PTSD) - Drug Profiles

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects

Post-Traumatic Stress Disorder (PTSD) - Discontinued Products

Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019

Number of Products under Development by Companies, H1 2019

Number ...

List of Tables

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Anagin Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Armgo Pharma Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Artelo Biosciences Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2019

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2019 (Contd..1), H1 2019

Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019

Number of Products under Development by Companies, H1 2019

Number ...

List of Figures

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports